HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Benzinga Newsdesk www.benzinga.com Positive 72.9%

Neg 0% Neu 0% Pos 72.9%

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $100 to $115.